With the introduction of differentiating brokers, similar to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the outcomes of sufferers with acute promyelocytic leukemia (APL) have considerably improved [1, 2]. Nonetheless, there are nonetheless many early deaths, particularly amongst these at excessive threat [3, 4]. In our retrospective examine of 570 sufferers with APL, early mortality was 7.54% [5]. We noticed sudden and preventable early deaths, primarily brought on by steroid-unresponsive differentiation syndrome (DS) and deadly hemorrhage.
Prophylaxis towards DS with steroids is really useful for sufferers with elevated white blood cell (WBC) counts [6, 7]. Nonetheless, the optimum scheme stays controversial. Moreover, sufferers with DS insensitive to steroids usually have a poor prognosis, highlighting the need for improved administration methods on this space. On this examine, sufferers acquired various doses of dexamethasone for DS prophylaxis and the efficacy and security of ruxolitinib had been explored as a second-line remedy for DS, with the purpose of decreasing early mortality in APL sufferers.
This Section 3 multicenter single-arm APL-01 trial (NCT04446806) enrolled beforehand untreated sufferers with APL. The current evaluation was carried out in September 2023, with a median follow-up of 34 months. All sufferers acquired induction remedy with ATRA (25 mg/m2) together with both intravenous ATO (0.16 mg/kg capped at 10 mg) or oral tetra-arsenic tetra-sulfide (As4S4) components named the Realgar-Indigo naturalis components (RIF) (60 mg/kg) [8]. Bone marrow aspirate was evaluated after restoration of blood cell counts. The prevention routine for DS was primarily based on the WBC rely at presentation and after the initiation of ATRA, which included cytoreductive brokers and dexamethasone (Fig. 1A). The prognosis and grading standards for DS had been per these of the PETHEMA group [9], detailed descriptions can be found within the Supplementary Appendix.
A Prophylaxis towards APL DS. B Administration for APL DS. aIf the WBC rely exceeded 10 × 109/L, 4-6 doses of IDA (2-5 mg/dose) had been administrated 72 hours after initiation of ATRA in case of deadly bleeding threat. bAdministrated DXMS 10 mg twice every day promptly on the earliest symptom or signal suggestive of DS, similar to dyspnea, unexplained fever, weight achieve larger than 5 kg, unexplained hypotension, acute renal failure, pulmonary infiltrates, or pleuropericardial effusion. cSufferers ought to be intently monitored. If the signs/indicators didn’t enhance inside 24 hours or worsened in 8 hours (e.g., shortness of breath, slight hemoptysis, decrease blood oxygen saturation, high-flow oxygen remedy requirement, and progressive oliguria), ruxolitinib ought to be initiated. dThe collection of completely different doses of ruxolitinib ought to be primarily based on a complete analysis of the severity of DS, age, weight, basic situation, and accompanying comorbidities. eThe small print of aggressive supportive care can be found within the Supplementary Appendix. WBC white blood cell, ATRA all-trans retinoic acid, HU hydroxyurea, DXMS dexamethasone, IDA idarubicin, DS differentiation syndrome.
When DS was suspected, immediate initiation of remedy with intravenous dexamethasone (20 mg/day) was administrated. If a positive response was achieved, dexamethasone might be progressively tapered. Nonetheless, if the signs/indicators didn’t enhance inside 24 hours or worsened in 8 hours, ruxolitinib (5-20 mg bid) ought to be initiated promptly, with the dosage decided by the severity of DS, age, weight, basic situation, and accompanying comorbidities. As soon as important enchancment was noticed, the doses of dexamethasone and ruxolitinib might be alternately decreased. Conversely, if sufferers progressed to renal failure or respiratory failure and wanted to be admitted to the Intensive Care Unit, ATRA/arsenic remedy ought to be discontinued. As soon as signs had utterly resolved, ATRA/arsenic might be restarted (Fig. 1B). The first examine endpoint was the incidence of DS and extreme DS, in addition to early loss of life. Secondary endpoints included full remission (CR) fee, evaluation of poisonous results throughout induction, recurrence-free survival (RFS) and total survival (OS).
Between June 1, 2019, and December 31, 2021, 111 sufferers recognized with APL had been included on this trial from 14 facilities in China (Desk 1). Amongst these sufferers, 33 had been categorised as high-risk sufferers (WBC rely at prognosis > 10 × 109/L) and 78 as low-risk sufferers (WBC rely at prognosis ≤ 10 × 109/L). The median WBC rely earlier than remedy in high-risk sufferers was 21.51 × 109/L, with 10 sufferers having a rely exceeding 50 × 109/L. No sufferers withdrew from the examine because of both remedy refusal or extreme toxicity.
All high-risk sufferers and 57 out of 78 low-risk sufferers acquired dexamethasone (5-10 mg/day) for DS prophylaxis. Preemptive remedy with dexamethasone (10 mg each 12 hours) was administered to 65 sufferers (40 low-risk and 25 high-risk) because of suspected DS. Among the many complete 111 sufferers, 41 (36.9%) had been finally recognized with DS, with 25 (22.5%) categorised as reasonable circumstances and 16 (14.4%) as extreme circumstances (Desk 1). The incidence of DS and extreme DS was greater in high-risk sufferers in comparison with low-risk sufferers (48.5% vs. 32.1%, 24.2% vs. 10.3%), whereas these variations weren’t statistically important (p = 0.057, p = 0.056) (Determine S1). DS occurred at a median of 8 days after the initiation of ATRA administration, with a variety of 2-21 days. The commonest options of DS included weight achieve (85%), pulmonary infiltrates (78%), and dyspnea (71%). Moreover, sufferers with extreme DS exhibited the next prevalence of dyspnea (p = 0.013), pleuropericardial effusion (p = 0.018), and acute renal dysfunction (p = 0.009) in comparison with reasonable circumstances (Desk S1).
23 out of the 41 sufferers with DS skilled a fast remission with preemptive remedy. Nonetheless, the situation of the remaining sufferers with extreme DS (12 sufferers) and reasonable DS (6 sufferers) worsened (Desk S2). All of them acquired ruxolitinib, with 12 responding properly, whereas the opposite 6 required non-invasive mechanical air flow and discontinued ATRA. 5 of them recovered inside 72 hours, and one affected person was efficiently weaned from the ventilator 10 days later. None of them developed ventilator dependency or required invasive mechanical air flow. The median period of ruxolitinib remedy was 12.5 days, starting from 8 to 17 days (Desk S3).
In our examine, 24 out of 65 sufferers who acquired preemptive remedy (17 low-risk and seven high-risk) had been finally not categorized as having DS. Amongst them, 20 circumstances exhibited weight achieve, 2 skilled unexplained fever, and a pair of offered with transient pulse oxygen decline. All sufferers rapidly improved after receiving dexamethasone mixed with supportive remedy similar to diuretics, antibiotics, and oxygen inhalation. Though it can’t be utterly dominated out that these sufferers might have exhibited early manifestations of DS, fluid overload and an infection couldn’t be dominated out both. Moreover, in response to the diagnostic standards for DS, a single signal or symptom of DS alone was not thought-about adequate to make a prognosis of DS [9]. Subsequently, these 24 sufferers weren’t thought-about for inclusion within the DS class.
The general 30-day mortality fee was 1.8% (2/111), with two high-risk sufferers succumbing to intracranial hemorrhage. There have been no deaths attributed to DS or an infection. The general CR fee was 98.2%.
Early administration of leukocytosis is essential in stopping DS and usually entails using cytoreductive brokers and steroids. On this examine, our tailor-made remedy routine for complete prophylaxis towards DS was proved efficient in managing hyperleukocytosis. The incidence of DS at 36.9% was barely greater in our examine in comparison with earlier literatures [2, 9], which might be attributed to improved recognition of the syndrome and the next proportion (roughly 30%) of high-risk sufferers. Notably, in contrast to findings from different research [9, 10], our outcomes didn’t reveal a major distinction within the incidence of DS and extreme DS amongst sufferers with completely different threat profiles, highlighting that high-risk sufferers might derive larger profit from prophylactic measures.
Speedy decision of signs was noticed in solely 56% of DS sufferers who acquired preemptive dexamethasone with steady ATRA remedy. The distinctive traits of promyelocyte maturation and tissue infiltration in DS might exacerbate the cell-mediated coagulopathy of APL [9, 11], placing these people at a excessive threat of deadly hemorrhagic occasions. Within the PETHEMA examine, 61% of DS sufferers discontinued ATRA, with 8% of them succumbing to hemorrhage [9]. Among the many 19 circumstances of early hemorrhagic deaths in our earlier examine [5], 6 sufferers stopped ATRA because of DS, and three sufferers with hyperleukocytosis at presentation solely acquired ATO to mitigate DS dangers. Hesitation or early suspension of ATRA because of DS will increase the chance of bleeding in newly recognized APL sufferers.
In some circumstances, DS can nonetheless manifest as a fulminant course even after discontinuing ATRA. Though accompanied by typical DS signs, hemoptysis in these sufferers is often believed to be brought on by coagulation issues. Nonetheless, Nicolls et al [12] recognized diffuse alveolar hemorrhage as a uncommon symptom of DS ensuing from endothelial harm in 1998. In our examine, 4 out of the 5 sufferers with hemoptysis (circumstances 2, 6, 7, and 40) had been additionally creating DS concurrently (Desk S4). When put next with sufferers with intracranial hemorrhage, three sufferers with hemoptysis confirmed important enchancment in coagulopathy, they recovered solely after ruxolitinib was initiated. It’s conceivable that hemoptysis might manifest on account of lung harm in DS.
Though the precise pathogenesis of DS is unknown, differentiation remedy might induce the manufacturing of chemokines within the lung and in APL cells, each of which set off the migration of leukemic cells. Pulmonary infiltration of activated leukocytes might induce an uncontrollable systemic hyperinflammatory response generally known as cytokine launch syndrome (CRS) [13]. Subsequently, we hypothesized that interventions such because the selective JAK1/2 inhibitor, ruxolitinib, aimed toward modulating the immune response and suppressing exacerbating hyperinflammation would possibly assist resolve this complicated difficulty.
The efficacy of ruxolitinib for steroid-refractory DS was 67% when ATRA was maintained. After discontinuing ATRA remedy, the remaining sufferers recovered. In distinction, DS-associated mortality was 8%-11% in different trials [9, 10, 14]. Moreover, within the security evaluation (Supplementary Appendix), because of progressive tapering of the doses inside a short course and minimal chemotherapy, the incidence of grade 4 neutropenia didn’t differ considerably between sufferers with or with out DS. An infection occurred in 40% of all sufferers on this examine, a decrease fee in comparison with sufferers within the APL15 trial [15], utilizing ATRA-ATO induction with out chemotherapy (50%).
In conclusion, our knowledge assist the feasibility and advantages of the personalised methods together with steroids and ruxolitinib for managing DS in APL, leading to a discount of early loss of life.
